Radial: EU Retailers Failing to Meet Customer Expectations beyond the Point of Purchase
Today Radial, the omnichannel technology solutions company, releases its annual eDelivery Index 2017, highlighting the hidden customer service failings of retailers across the UK, Italy, Germany and Spain.
In the Age of Immediacy, where a taxi can be ordered in minutes, movies streamed in seconds and consumers can receive goods on next or same day delivery – consumer expectation is high. Despite this, the research has revealed that only half of retailers offer an express delivery option, whilst a paltry 6% offer same day delivery.
Demand for Now
Given this Demand for Now, the research reveals that when it comes to delivery and returns consumer convenience is a top priority. In terms of delivery choices, many retailers have caught on to the advantages of offering flexible options, with 2.7 options available on average – while the UK firmly leads the way with 4.4 delivery options.
However, charges on any of these options will soon be a deterrent to today’s entitled customer - with findings that 79% of retailers now offer free standard home delivery, and 95% offer free Click & Collect as an alternative to paid postal service.
Missed Opportunity with Click & Collect
Click & Collect remains popular across all countries with 95% of retailers offering the service, as it not only provides accessibility for the customer but also enables retailers to benefit from the additional footfall of driving customers to stores. Yet despite the obvious cost and flexibility advantages, few retailers are utilising in-store stock to service consumer orders - as indicated by the closely matching local average speeds of Standard home delivery with 3.1 days and Click & Collect with 3.2 days. Utilising this in-store stock will not only cater to the immediacy that many customers desire, but would also drive significant cost reductions in serving such orders.
The Evolution of Click & Collect
As an alternative trend, the research shows that delivery options now extend beyond Click & Collect, with on average 34% of retailers also offering convenience stores. This is a serious competitor issue for non-local retailers with 70% failing to provide this option.
Ben Willis, Managing Director International at Radial comments: “This research shows that for European retailers today, a ubiquitous omnichannel offering is simply not the reality. These findings are a proof point that today’s retailers need to reassess their customer experience strategy to look at the bigger picture.
The ubiquity of online and mobile commerce means that brand competition has reached previously unimaginable levels and is threatening to destroy customer loyalty altogether. The likes of Amazon have created consumer expectation for a whole new level of customer experience - and this needs to be considered when it comes to delivery and returns. For retailers to deliver a true omnichannel experience they need to consider how they engage with customers beyond the point of purchase, prioritise delivery and returns that meets the needs for customers – ensuring repeat business.”
Lastly, a much-underestimated aspect of the customer journey is consumer convenience and costliness of returns. Research shows, brands offer a satisfactory selection of on average 1.9 return options; however, they are lacking in offering in-store return options. With only 52% of retailers providing this free avenue to consumers, the research suggests that retailers are placing immediate profits above long-term revenue. The in-store return method offers a significant opportunity to cut down the cost of returns by promoting exchanges and refunds and assimilating in-store returns directly into store inventory.
About Radial’s European eDelivery Index
The full report can be downloaded here
If local or non-local retailer is not specified the figure is based on the average from 150 of Europe’s biggest online retailers, both local and non-local.
Radial is the leader in omnichannel commerce technology and operations, enabling brands and retailers to profitably exceed retail customer expectations. Radial's technical, powerful omnichannel solutions connect supply and demand through efficient fulfilment and transportation options, intelligent fraud detection, payments, and tax systems, and personalized customer care services.
Hundreds of retailers and brands confidently partner with Radial to simplify their post-click commerce and improve their customer experiences. Radial brings flexibility and scalability to their supply chains and optimizes how, when and where orders go from desire to delivery. Learn how we work with you at www.radial.com.
For more information, please contact:
Siobhan Eyres or Shannon Tweed
Tel: 01869 715090
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Record Attendance at Japan Content Showcase 2017!20.11.2017 06:00 | Tiedote
Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 03:01 | Tiedote
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®20.11.2017 01:21 | Tiedote
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 19:31 | Tiedote
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases19.11.2017 02:00 | Tiedote
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 21:20 | Tiedote
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme